Three rapid-growth stocks have significantly outperformed the broader market in early 2026. Corvus Pharmaceuticals surged 188% YTD on positive Phase 1 trial data for its atopic dermatitis drug candidate soquelitinib, with a Phase 2 trial planned for early 2026. New Era Energy & Digital jumped 114% YTD following strategic partnerships in the data center space, though it faces legal scrutiny. USA Rare Earth gained 56% YTD, supported by $1.6 billion in federal investment and strong cash position, though it remains an early-stage firm without proven profitability.

Corvus Pharmaceuticals successfully closed an upsized public offering of 9,085,778 shares at $22.15 per share, generating approximately $201.2 million in gross proceeds. The company plans to use the net proceeds for working capital, R&D including Phase 3 T cell lymphoma and Phase 2 atopic dermatitis trials, and general corporate purposes.

Corvus Pharmaceuticals priced an upsized underwritten public offering of 7.9 million shares at $22.15 per share, raising approximately $175 million in gross proceeds. The company plans to use the funds for working capital, R&D including Phase 3 T cell lymphoma and Phase 2 atopic dermatitis trials, and general corporate purposes. The offering is expected to close on January 23, 2026.

Corvus Pharmaceuticals presented interim data from a Phase 1b/2 clinical trial of ciforadenant for metastatic renal cell cancer, showing promising results when combined with ipilimumab and nivolumab, with a 34% deep response rate and favorable safety profile.

Over 20 pharmaceutical companies are actively developing Interleukin-2 (IL-2) inhibitors to address autoimmune diseases and organ transplant procedures, with promising pipeline drugs in various clinical trial stages.

U.S. stock futures climbed on Wednesday as investors await the Federal Reserve's interest rate decision and economic data releases. The Dow Jones index extended its losing streak to nine consecutive sessions, the longest since 1978.

Corvus Pharmaceuticals presented new preclinical data showing that their lead ITK inhibitor, soquelitinib, can prevent lung damage, inflammation, and pulmonary hypertension in mouse models of systemic sclerosis, an autoimmune disease. The data supports the potential of ITK inhibition as a novel therapeutic approach for immune-mediated fibrotic diseases.

Corvus Pharmaceuticals presented new data at the SITC Annual Meeting showing that their drug ciforadenant has the potential to overcome resistance to immunotherapy in metastatic castration-resistant prostate cancer. The data suggests ciforadenant can reduce immunosuppression and enhance sensitivity to anti-PD1 therapy.

The article discusses the T-cell lymphoma drug pipeline, highlighting the development of novel therapies by companies like Eisai, Takeda, and Rhizen Pharmaceuticals. Regulatory agencies are providing support to accelerate the development of these treatments, addressing the urgent need for better options in this challenging condition.

Soquelitinib Phase 1 Randomized Trial in Atopic Dermatitis Enrolling at Multiple Centers; Potential for Early Data Before Year-End 2024

Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT

BURLINGAME, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today announced that it has entered into a securities purchase agreement with new and existing investors to raise approximately $30.6 million dollars in aggregate gross proceeds through the sale of shares of its common stock, par value $0.0001 per share (the “Common Stock”) and pre-funded warrants to purchase Common Stock in lieu thereof (the “Pre-Funded Warrants”), and accompanying common warrants to purchase Common Stock (or Pre-Funded warrants in lieu thereof) (the “Common Warrants,” and together with the Common Stock and Pre-Funded Warrants, the “Securities”), excluding the proceeds, if any, from the exercise of the Pre-Funded Warrants and the Common Warrants and before deducting offering expenses.